Christoph Boss completed his PhD in synthetic organic chemistry at the University of Bern (Prof. Reinhart Keese), Switzerland followed by post-doctoral training at The Scripps Research Institute (TSRI; Prof. Julius Rebek, Jr.) in LaJolla, California, USA.
From 1999 until 2012, he had various positions of increasing responsibility in Actelion's drug discovery chemistry department contributing to the identification of several lead compounds including macitentan (Opsumit) for PAH and daridorexant (Quviviq) for insomnia. From November 2012 to June 2017, he was the Senior Group Leader Chemistry Technologies at Actelion Pharmaceuticals Ltd. He joined Idorsia when the company was established in June 2017 as the Senior Group Leader in Drug Discovery Chemistry, Oncology. He was appointed Head of Drug Discovery Chemistry and member of the Idorsia leadership team in July 2019. In 2019, Christoph Boss received the SCS Industrial Science Award from the Swiss Chemical Society.
